Company: BNBX
Filing Date: 2025-01-10
Form Type: S-1/A
Source: 0001104659-25-002521
Chunk: 6

Company: BNB PLUS CORP.
Filing Date: 2025-01-10
Form: S-1/A
Chunk 6
---
 that you should consider
before investing in our securities. After you carefully read this summary, to fully understand our Company and this offering and its
consequences to you, you should read this entire prospectus and any related free writing prospectus authorized by us, including the
information referred to under the heading “Risk Factors” in this prospectus beginning on page 8, and any related
free writing prospectus, as well as the other documents that we incorporate by reference into this prospectus, including our
financial statements and the notes to those financial statements, which are incorporated herein by reference from our Annual Report on Form 10-K for the year ended September 30, 2024, filed on December 17, 2024. Please read “Where You Can
Find More Information” on page 23 of this prospectus.

In this prospectus, unless context requires otherwise,
references to “we,” “us,” “our,” or “the Company” refer to Applied DNA Sciences, Inc.,
a Delaware corporation and its consolidated subsidiaries. Our trademarks currently used in the United States include Applied DNA Sciences®,
SigNature® molecular tags, SigNature® T molecular tags, fiberTyping®, SigNify®, Beacon®, CertainT®, LineaDNA®,
Linea RNAP, Linea™ COVID-19 Diagnostic Assay Kit, safeCircle® COVID-19 testing and TR8 pharmacogenetic
testing. We do not intend our use or display of other companies’ trade names or trademarks to imply a relationship with, or endorsement
or sponsorship of us by, any other companies. All trademarks, service marks and trade names included in this prospectus are the property
of the respective owners.

<div align='center'>1</div>

Applied DNA Sciences, Inc.

Introduction

We are a biotechnology company developing and
commercializing technologies to produce and detect deoxyribonucleic acid (“DNA”) and ribonucleic acid (“RNA”).
Using polymerase chain reaction (“PCR”) to enable the production and detection of DNA and RNA, we currently operate in three
primary business markets: (i) the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics
(including biologics and drugs), as well as the development and sale of a proprietary RNA polymerase (“RNAP”) for use
in the production of messenger RNA (“mRNA”) therapeutics (“Therapeutic DNA Production Services”); (ii) the
detection of DNA and RNA in